This company is a pharmaceutical company whose activities include the production and development of fermentation derived APIs and dosage forms. This company has an involvement in the field of immunosuppressants, anti-infectives, and other pharmaceuticals. Its products cater to domestic as well as international markets.
The shares of Concord Biotech are currently trading at Rs. 1,506.40, down by 3.49%. The company has a market capitalization of Rs. 15,759.38 crore. The stock’s 52week high is Rs. 1,667.60 and its 52 week low is Rs. 987.00. In the past 6 months the stock has delivered a return of 45.01%.
What’s The News
Proposal for bonus share has been passed by the board of directors of Concord Biotech. The ratio of the bonus share to be issued is 1:1. It implies that any shareholder having an equity share of Rs. 1 would receive a bonus share of Rs. 1 as well.
The Company currently holds 10,46,16,204 fully paid up equity shares of Rs. 1 each. Therefore, with the proposed bonus shares issue, the Company will be issuing the same number of bonus shares such that the total number of equity shares held by the Company will be 20,92,32,408, post the issue of bonus shares.
Bonus Issue Details
Concord Biotech Limited has announced a scheme of 1:1 bonus share, according to which shareholders who are eligible will be entitled to receive one extra equity share for each equity share held. Concord Biotech Limited has currently 10,46,16,204 equity shares with the face value of Rs. 1 per share. After issuing bonus shares, the total number of equity shares will be 20,92,32,408.
The bonus issue proposal will entail the issuing of 10,46,16,204 bonus shares, with an estimated issue value of approximately Rs. 10.46 crore. The bonus shares will be allotted out of the company’s share premium account. At the end of the financial year ending on March 31, 2026, the share premium account balance was approximately Rs. 81.97 crore out of which Rs. 10.46 crore will be capitalized towards the proposed bonus issue.
The record date for identifying eligible shareholders has yet to be decided. The proposed bonus issue will also be subject to the mandatory approval of the shareholders and any other required regulatory approvals. Upon completion of the issue, the equity shares will be doubled, whereas the face value of the shares will be the same – Rs. 1 per share.
Increase in Authorised Share Capital
Along with the bonus issue, Concord Biotech’s Board has approved an increase in the company’s authorised share capital from Rs. 11 crore to Rs. 22 crore. This involves the creation of an additional 11 crore equity shares of Rs. 1 each, subject to the necessary approvals.
The increase in authorised capital will support the expanded paid-up share capital following the proposed bonus issue. The company will also amend the relevant clause of its Memorandum of Association to reflect the revised authorised capital.
What Does 1:1 Bonus Issue Mean?
Under the proposed 1:1 bonus issue, an eligible shareholder holding 100 shares on the record date would receive another 100 bonus shares, taking the total holding to 200 shares. The bonus shares are issued without any additional payment by eligible shareholders.
However, a bonus issue does not by itself increase the value of an investor’s overall holding at the time of issuance, as the number of shares doubles while the theoretical per-share price adjusts correspondingly. The company’s underlying business, earnings and valuation continue to determine the market value of the investment.
Record Date and Timeline
Concord Biotech has not yet announced the record date for determining shareholders eligible to receive the bonus shares. The company has indicated that the bonus shares are expected to be credited or dispatched within two months from the date of the Board approval, subject to completion of the required approvals and procedures.
The proposed bonus issue is therefore not yet completed. Shareholders will first need to approve the proposal, following which the company will announce the applicable record date and complete the allotment process.
Investor Perspective
The 1:1 bonus issue will increase Concord Biotech’s number of outstanding shares from 10.46 crore to 20.92 crore, while the face value of each share will remain at Rs. 1. The move is being funded through the company’s existing share premium rather than through a fresh cash raising.
For investors, the key dates to track will be the shareholder approval, record date, allotment and credit of the bonus shares. The bonus issue changes the number of shares held by eligible shareholders but does not, by itself, alter the underlying operating performance or intrinsic economics of the business.